Dr. Desjardins is currently CEO of Clementia Pharmaceuticals, a privately held, clinical-stage biotechnology company dedicated to the development and commercialization of new treatments for people suffering from Fibrodysplasia Ossificans Progressiva, an extremely rare and disabling genetic disease of the connective tissues.
Most recently, Dr. Desjardins was the CEO of the Centre of Excellence in Personalized Medicine (CEPMED), a federally funded not-for-profit organization. Prior to this, she was a serial entrepreneur, taking part in all aspects of company creation, from conception, to financing, to the marketplace. She founded Advanced Bioconcept, a research reagent and diagnostics company sold to NEN Life Sciences (Perkin Elmer) in 1998. She also co-founded Caprion Pharmaceuticals (now Thallion, a TSX-listed company), a biotechnology company focused on proteomic biomarker discovery and drug development, where she was Executive Vice-President of Corporate Development.
Dr. Desjardins received the BRIO award for outstanding contributions to the biotechnology industry from the Quebec Biotechnology Association. She was also nominated for the Ernst & Young Entrepreneur of the Year award and was named one of Canada’s top young Canadians likely to influence the future by the Globe and Mail. Dr. Desjardins earned a PhD in Neurology and Neurosurgery from McGill University’s Faculty of Medicine and was a Medical Research Council postdoctoral fellow at the Douglas Hospital Research Centre.